Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anteris Technologies (AVR) reports eight patients showed clinically significant improvements under the first-in-human DurAVR Transcatheter Heart Valve (THV) study
  • There was an 81 per cent decrease in the mean pressure gradient and an average 300 per cent increase in effective orifice area
  • The study is being performed at the Tbilisi Heart and Vascular Clinic in Georgia with all 13 patients continuing to show marked improvements from their pretreatment levels
  • This data comes from 30-day follow-up results with further data to be released at the 12-month mark
  • Shares in Anteris are down a slight 0.89 per cent and were trading at $27.80 at 11:47 am AEST

Anteris Technologies (AVR) has reported eight patients showed clinically significant improvements under the first-in-human DurAVR Transcatheter Heart Valve (THV) study.

There was an 81 per cent decrease in the mean pressure gradient with patients ranging from -89 to -74 per cent and an average 300 per cent increase in effective orifice area ranging from 217 to 582 per cent.

The study is being performed at the Tbilisi Heart and Vascular Clinic in Georgia with all 13 patients continuing to show marked improvements from their pretreatment levels.

This data comes from 30-day follow-up results with further data to be released at the 12-month mark.

The THV is designed to be a functional cure for severe aortic stenosis which is a condition where the heart’s aortic valve narrows, reducing blood flow to the body and forcing the heart to work faster.

“The data so far is extremely encouraging and fulfilling the hypothesis that DurAVR works
better and lasts longer. As we move into the second half, we will continue enrolling patients into our studies (Europe and FDA EFS) and gathering data for presentation at the major conferences as well as regulatory filings throughout the rest of the year,” CEO Wayne Paterson said.

“We will continue generating non-patient data as well with leading research institutions that demonstrate DurAVR’s superior flow characteristics compared with competitor valves as well as other relevant data.”

Shares in Anteris were down a slight 0.89 per cent and were trading at $27.80 at 11:47 am AEST.

AVR by the numbers
More From The Market Herald
MetalsGrove Mining (ASX:MGA) - Managing Director, Sean Sivasamy

" MetalsGrove Mining (ASX:MGA) begins soil sampling at Upper Coondina

MetalsGrove Mining (ASX:MGA) has begun a soil sampling program at its Upper Coondina lithium project in…
Bellavista Resources (ASX:BVR) - Non Executive Chairman, Mel Ashton

" Bellavista Resources (ASX:BVR) commissions second rig for Brumby, WA

Bellavista Resources (ASX:BVR) has commissioned a second rig to begin drilling at its Brumby zinc-silver-copper project…

" Sky Metals (ASX:SKY) encounters further tin mineralisation at Tallebung, NSW

Sky Metals (ASX:SKY) has reported further tin mineralisation at its Tallebung tin project in New South…
Spectur (ASX:SP3) - Managing Director, Gerard Dyson

" Spectur (ASX:SP3) raises $1.15m in SPP

Spectur (ASX:SP3) has raised $1.15 million through a security purchase plan (SPP) and shortfall offer.